Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 341


Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.

Smith HA, McNeel DG.

J Immunother. 2011 Oct;34(8):569-80. doi: 10.1097/CJI.0b013e31822b5b1d.


Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.

Smith HA, Cronk RJ, Lang JM, McNeel DG.

Cancer Res. 2011 Nov 1;71(21):6785-95. doi: 10.1158/0008-5472.CAN-11-2127.


DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.

Smith HA, Rekoske BT, McNeel DG.

Vaccine. 2014 Mar 26;32(15):1707-15. doi: 10.1016/j.vaccine.2014.01.048.


Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.

He Y, Mao L, Lin Z, Deng Y, Tang Y, Jiang M, Li W, Jia Z, Wang J, Ni B, Wu Y.

Mol Immunol. 2008 May;45(9):2455-64. doi: 10.1016/j.molimm.2008.01.014.


CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.

Olson BM, McNeel DG.

Cancer Immunol Immunother. 2011 Jun;60(6):781-92. doi: 10.1007/s00262-011-0987-5.


Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.

Johnson LE, McNeel DG.

Prostate. 2012 May 15;72(7):730-40. doi: 10.1002/pros.21477.


Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ.

Hum Immunol. 2000 Aug;61(8):764-79.


Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.

Peng S, Trimble C, He L, Tsai YC, Lin CT, Boyd DA, Pardoll D, Hung CF, Wu TC.

Gene Ther. 2006 Jan;13(1):67-77.


Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.

Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, Pfreundschuh M, Speiser D, Lévy F.

J Immunol. 2002 Feb 15;168(4):1717-22.


HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.

Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG.

Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6.


A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.

Tu SH, Huang HI, Lin SI, Liu HY, Sher YP, Chiang SK, Chong P, Roffler S, Tseng GC, Chen HW, Liu SJ.

J Immunother. 2012 Apr;35(3):235-44. doi: 10.1097/CJI.0b013e318248f2ae.


Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.

Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, Speiser D.

Cancer Res. 2003 Sep 1;63(17):5601-6.


HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.

Guo J, Li G, Tang J, Cao XB, Zhou QY, Fan ZJ, Zhu B, Pan XH.

Scand J Immunol. 2013 Sep;78(3):248-57. doi: 10.1111/sji.12083.


In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.

Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY.

J Natl Cancer Inst. 1997 Feb 19;89(4):293-300.


Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.

Liu W, Zhai M, Wu Z, Qi Y, Wu Y, Dai C, Sun M, Li L, Gao Y.

Amino Acids. 2012 Jun;42(6):2257-65. doi: 10.1007/s00726-011-0966-3.


Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.

Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA.

Cancer Res. 2004 Apr 1;64(7):2610-8.


Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.

Wagner C, Neumann F, Kubuschok B, Regitz E, Mischo A, Stevanovic S, Friedrich M, Schmidt W, Rammensee HG, Pfreundschuh M.

Cancer Immun. 2003 Dec 17;3:18.


Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.

Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR, Mohanakumar T.

Breast Cancer Res Treat. 2004 Nov;88(1):29-41.


Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.

Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J.

Cancer Res. 1997 Oct 15;57(20):4570-7.


Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.

Kissick HT, Sanda MG, Dunn LK, Arredouani MS.

Cancer Immunol Immunother. 2013 Dec;62(12):1831-40. doi: 10.1007/s00262-013-1482-y.

Items per page

Supplemental Content

Support Center